Abstract: An example system includes a processor to receive a stream of records. The processor can generate an unbiased outlier score for each sample in the stream of records via a trained histogram-based outlier score model. The unbiased outlier score is unbiased for samples including dependent features using feature grouping. The processor can then detect an anomaly in response to detecting that an associated unbiased outlier score of the sample is higher than a predefined threshold.

Abstract: In a cartridge device for analyzing a body liquid, a first member of the cartridge has two or more wells for performing assays, and a second member of the cartridge has a compartment for holding one or more disposable pipette tips.

Abstract: In some examples, a system for decorating network traffic flows with outlier scores includes a processor and a memory device to store traffic flows received from a network. The processor is configured to receive a set of traffic flows from the memory device and generate a tree model to split the traffic flows into clusters of traffic flows. Each cluster corresponds with a leaf of the tree model. The processor is further configured to generate machine learning models for each of the clusters of traffic flows separately. For a new traffic flow, the processor is configured to identify a specific one of the machine learning models that corresponds with the new traffic flow, compute an outlier score for the new traffic flow using the identified specific one of the machine learning models, and decorate the new traffic flow with the outlier score.

Abstract: The invention relates to a method for treating emergency spill or leak of halogen which is bromine or chlorine, comprising contacting an aqueous solution of quaternary ammonium halide with the halogen.

Abstract: The invention relates to a method for treating emergency spill or leak of halogen which is bromine or chlorine, comprising contacting an aqueous solution of quaternary ammonium halide with the halogen.

Abstract: Peptides predicted to be immunogenic against African swine fever virus (ASFV) and vaccine compositions that include the peptides are disclosed herein. In some embodiments, these compositions comprise or consist of one or more peptides comprising the amino acid sequence set forth in SEQ ID NOs: 2-2273. In other embodiments, the compositions comprise viral vectors or host cells, or combinations thereof, that comprise one or more of the peptides. In other embodiments, the compositions comprise nucleic acid molecules comprising one or more of the peptides. The compositions disclosed can include one or more additional components, such as, but not limited to, a carrier, an adjuvant, an additional therapeutic, or combinations thereof. Containers and kits that comprise the compositions are described. Uses of the compositions can include administration to an animal to induce an immune response in the animal, or to immunize the animal against ASFV.

Abstract: An isolated monoclonal antibody or antigen-binding fragment thereof binds to F. tularensis lipopolysaccharide (Ft LPS). The antibody preferably lacks an Fc region or has an impaired Fc-region. The antibody may be formulated into a pharmaceutical composition along with a pharmaceutically acceptable carrier, excipient or diluent. It may be provided in a kit with means for detection of the antibody and instructions for use. A therapeutically effective amount of such an antibody can be used for prophylaxis, treatment or amelioration of Ft infection and for inhibiting Ft uptake by cells in a subject. The antibody can also be used to detect Ft infection. Also disclosed is an isolated nucleic acid molecule encoding the antibody, an expression vector having the isolated nucleic acid molecule, and a host cell transfected with such an expression vector.

Abstract: An isolated monoclonal antibody or antigen-binding fragment thereof binds to F. tularensis lipopolysaccharide (Ft LPS). The antibody preferably lacks an Fc region or has an impaired Fc-region. The antibody may be formulated into a pharmaceutical composition along with a pharmaceutically acceptable carrier, excipient or diluent. It may be provided in a kit with means for detection of the antibody and instructions for use. A therapeutically effective amount of such an antibody can be used for prophylaxis, treatment or amelioration of Ft infection and for inhibiting Ft uptake by cells in a subject. The antibody can also be used to detect Ft infection. Also disclosed is an isolated nucleic acid molecule encoding the antibody, an expression vector having the isolated nucleic acid molecule, and a host cell transfected with such an expression vector.

Abstract: Fusion polypeptides are provided including modified human Acetylcholinesterase conjugated to the Fc region of an immunoglobulin. Methods of preparing these polypeptide constructs and uses thereof as scavenging agents of organophosphate compounds are described.

Abstract: An electronic circuit includes a first oscillator, a second oscillator and ancillary circuitry. The first oscillator is configured to generate a first clock signal and has a first wake-up delay. The second oscillator is configured to generate a second clock signal and has a second wake-up delay that is shorter than the first wake-up delay. The ancillary circuitry is configured to provide the second clock signal as an output clock signal during wake-up of the first oscillator, and, following the first wake-up delay, to provide the first clock signal as the output clock signal.

Abstract: The invention provides an isolated Bacillus cereus sensu lato strain, selected from Bacillus anthracis, Bacillus cereus and Bacillus thuringiensis, in which the htrA gene or any part thereof is silenced, and vaccines comprising the same.

Abstract: Fusion polypeptides are provided including modified human Acetylcholinesterase conjugated to the Fc region of an immunoglobulin. Methods of preparing these polypeptide constructs and uses thereof as scavenging agents of organophosphate compounds are described.

Abstract: An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part of lysine residues in the hydrolase amino acid sequence is selected for the PEG-coupling, and the other part for the replacement, wherein the selection should ensure that the hydrolase surface shows at least one free amino acid for PEG coupling for all possible views obtained by rotating a 3-D model generated for the hydrolase.

Abstract: The invention provides an isolated Bacillus cereus sensu lato strain, selected from Bacillus anthracis, Bacillus cereus and Bacillus thuringiensis, in which the htrA gene or any part thereof is silenced, and vaccines comprising the same.

Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.

Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.

Abstract: A circulatory long-lived cholinesterase (ChE) protein, such as acetylcholinesterase (AChE) or butyrylcholinesterase (BChE), which is a ChE protein modified with a non-antigenic polymer. The ChE may be AChE, such as native AChE of mammalian origin or of non-mammalian origin, or recombinant AChE. The recombinant AChE may be mutated at one or more amino-acid residues. The BChE may be native BChE of mammalian origin or of non-mammalian origin.

Abstract: An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part of lysine residues in the hydrolase amino acid sequence is selected for the PEG-coupling, and the other part for the replacement, wherein the selection should ensure that the hydrolase surface shows at least one free amino acid for PEG coupling for all possible views obtained by rotating a 3-D model generated for the hydrolase.

Abstract: A circulatory long-lived cholinesterase (ChE) protein, such as acetylcholinesterase (AChE) or butyrylcholinesterase (BChE), which is a ChE protein modified with a non-antigenic polymer. The ChE may be AChE, such as native AChE of mammalian origin or of non-mammalian origin, or recombinant AChE. The recombinant AChE may be mutated at one or more amino-acid residues. The BChE may be native BChE of mammalian origin or of non-mammalian origin.